MedTrace Logo

Different Reversal Agents in Pediatric Day-case Cancer Surgery

NCT03996655 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-06-25

No results posted yet for this study

Summary

The aim of this study was to compare the efficacy of sugammadex and neostigmine on

reversing neuromuscular blockers in pediatric patients undergoing outpatient surgical

procedures.

Conditions

  • Post-operative Residual Curarization

Interventions

DRUG

Sugammadex Injection [Bridion]

Reversal of neuromuscular blockers

DRUG

Neostigmine

Reversal of neuromuscular blockers

Sponsors & Collaborators

  • National Cancer Institute, Egypt

    lead OTHER

Principal Investigators

  • Mohamed MO Hegazy, MD · Cairo University

  • Mohamed Ad Elramly, MD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2019-09-30
Completion
2019-10-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996655 on ClinicalTrials.gov